Rahman SH, Ammori BJ, Holmfield J, et al. Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis[J]. J Gastrointest Surg, 2003, 7(1): 26-35.
[4]
Harhaj NS, Antonetti DA. Regulation of tight junction and loss of barrier function in pathophysiology[J]. Int Biochem Cell Biol, 2004, 36(7): 1206-1237.
[5]
Frster C. Tight junctions and the modulation of barrier function in disease[J]. Histochem Cell Biol, 2008, 130(1): 55-70.
[6]
Forster C, Silwedel C, Golenhofen N, et al. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system[J]. J Physiol, 2005, 565(2): 475-486.
[7]
Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation[J]. Advanced Drug Delivery Review, 2005, 57: 883-917.
[8]
Cook D, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease[J]. Nature Immunology, 2004, 5(10): 975-979.
[9]
Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial cells[J]. Lab Invest, 2006, 86(1): 9-22.
[10]
Wu X, Yu M, Li A. Protective effect of a nuclear factor-kappaB inhibitor on ischemia-reperfusion injury in a rat epigastric flap model[J]. J Reconstr Microsurg, 2008, 24(5): 351-359.
[11]
Inoue S, Nakase H, Matsuura M, et al. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease[J]. Clin Exp Immunol, 2009, 156(1): 172-182.
